Abstract
The ultimate goal of COVID-19 vaccination campaigns is to enable the return of societies and economies to a state of normality. Presently, vaccines have not been approved for children. In this work, we use mathematical modeling and optimization to study the effect of the ineligibility of children for vaccination on the effectiveness of a vaccination campaign. Particularly, we address the question of whether vaccination of children of age 10 and older, once approved, should be given higher priority than the vaccination of other age groups. We consider optimal allocations according to competing measures and systematically study the trade-offs among them. We find that, under all scenarios considered, optimal allocations of vaccines do not include age-group 0-9. In contrast, in many of these cases, optimal allocations of vaccines do include the age group 10-19, though the degree to which inclusion of this age group improves outcomes varies by case.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3730/20) within the KillCorona: Curbing Coronavirus Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is based on the use of public aggregate data only and no medical intervention and is therefore exempt from institutional review board approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This work is based on the use of public aggregate data, which is fully available in the codes provided.
